Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
SNGX
SNGX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SNGX News
Soligenix Reports Q1 2026 Financial Results with $0.28 EPS
3d ago
seekingalpha
Soligenix Reports Q1 2026 Financial Results and Study Updates
3d ago
PRnewswire
SOLIGENIX RELEASES LATEST DEVELOPMENTS AND Q1 2026 FINANCIAL RESULTS
3d ago
moomoo
Latest Developments in the Biotech Sector
Apr 30 2026
NASDAQ.COM
Lucid, Soligenix, and Sportradar Shares Under Pressure Amid Setbacks
Apr 29 2026
stocktwits
Soligenix Faces Major Setback in Clinical Trial
Apr 28 2026
stocktwits
Soligenix Halts HyBryte Clinical Trial Due to Futility
Apr 28 2026
PRnewswire
Soligenix's FLASH2 Trial Halted Due to Futility, Future Uncertain
Apr 28 2026
Newsfilter
HyBryte™ Shows Promising Results in Treating Cutaneous T-Cell Lymphoma
Apr 02 2026
PRnewswire
Soligenix Reports FY EPS of -$2.14, Beats Estimates
Mar 31 2026
seekingalpha
Soligenix Reports 2025 Financial Results and Upcoming Milestones
Mar 31 2026
PRnewswire
Soligenix Reports 2025 Financial Results and Upcoming Milestones
Mar 31 2026
Newsfilter
Soligenix Receives EU Orphan Drug Designation for SGX945
Mar 26 2026
PRnewswire
Soligenix Receives EU Orphan Drug Designation for SGX945
Mar 26 2026
Newsfilter
Soligenix Highlights Positive Results for HyBryte™ in CTCL Treatment
Mar 23 2026
PRnewswire
Soligenix Highlights Positive Results for HyBryte™ in CTCL Treatment
Mar 23 2026
Newsfilter
Show More News
